Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

TAVR in Extremely Large Annuli: Different Patients Might Need Different Prostheses

Nearly all prostheses for transcatheter aortic valve replacement (TAVR) commercially available at present are adequate for most patients. However, there are certain subgroups, relatively small, that could benefit from a particular one. Yesterday we went over the best suited for small annuli, which turned out to be the self-expandable in general and the Evolut PRO in particular. Today we are reviewing a study that included the opposite population: patients presenting extremely large annuli. 

TAVI en anillos gigantes

The study included 105 patients with large annuli (mean annulus area 721.3 ± 36.1 mm2) from 15 centers undergoing TAVR with balloon expandable S3 between 2013 and 2018.

Mean age of patients was 76.9 ± 10.4 and the predicted surgical risk by STS was 5.2 ± 3.4%. 

At one year, global mortality and stroke rates were 18.2% and 2.4%, respectively. Baseline quality of life improved significantly at 30 days and one year (p<0.0001 for both).


Read also: TAVR in Small Annuli: Is There a Better Valve?


There was mild paravalvular regurgitation in 21.7% while moderate to greater occurred in 4.3% of patients. Gradients remained stable at one year. 

The last model of balloon expandable valves S3 seems more appropriate in patients with extremely large annuli, even though, as we concluded yesterday, more randomized studies are necessary for us to be able to determine what patients will benefit more from either of them.

Conclusion

Transcatheter aortic valve replacement with extremely large annuli is feasible with S3, with favorable clinical and electrocardiographic results at mid-term. 

Original Title: Mid-Term Outcomes of Transcatheter Aortic Valve Replacement in Extremely Large Annuli With Edwards SAPIEN 3 Valve.

Reference: Aditya Sengupta et al. J Am Coll Cardiol Intv 2019, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...